An interventional study of Non-Surgical Peri-implant Therapy (NSPT) and Minimally-Invasive Non-Surgical Therapy (MINST) in Peri-implantitis, Periodontitis and Non-surgical Periodontal Therapy, sponsored by St. Anne's University Hospital Brno, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-13.
Sponsored by St. Anne's University Hospital Brno, Czech Republic · Not applicable, Interventional, and Treatment
This multicenter, single-masked randomized controlled clinical trial evaluates the effectiveness of minimally-invasive non-surgical therapy (MINST) compared with standard non-surgical peri-implant therapy (NSPT) in patients diagnosed with peri-implantitis. The study investigates clinical outcomes, radiographic bone levels, patient-reported outcomes, and treatment time over 12 months.
Peri-implantitis is an inflammatory condition characterized by bleeding on probing, probing depths ≥6 mm, and radiographic bone loss. MINST is a refined, tissue-preserving approach using delicate ultrasonic tips under magnification, while NSPT includes ultrasonic debridement combined with steel curettes and soft-tissue curettage. Both treatments are standard of care.
The study includes 7 visits over 12 months, with clinical measurements, radiographs, plaque sampling, PROMs, and standardized instrumentation protocols.
322 studies on the registry are indexed under Peri-Implantitis; 88 are open to participants now.
This study's planned enrollment of 106 is above the median of 40 across 195 interventional studies indexed under Peri-Implantitis.
Browse Peri-Implantitis studies →St. Anne's University Hospital Brno, Czech Republic is the lead sponsor of 25 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
* Ultrasonic debridement with stainless steel tips * Steel curettes (Columbia 4R/4L) * Submucosal curettage * Local anesthesia
Procedure: Non-Surgical Peri-implant Therapy (NSPT)
* Exclusive use of thin, non-diamond ultrasonic tips (PS, PL1, PL2, Siroperio, Woodpecker P3, Acteon 10Z) * ≥3× magnification * Aim to obtain stable blood clot formation
Procedure: Minimally-Invasive Non-Surgical Therapy (MINST)
Standard mechanical debridement of the peri-implant pocket performed under local anesthesia. Treatment includes supra- and submucosal ultrasonic debridement using stainless-steel ultrasonic tips, followed by mechanical curettage of granulation tissue with steel curettes (Columbia 4R/4L). Soft-tissue curettage is performed from the inner aspect of the peri-implant pocket. No time restriction is imposed; the operator works until the implant surface is clinically clean.
Also known as: NSPT
Minimally invasive ultrasonic debridement performed under local anesthesia using exclusively thin, non-diamond ultrasonic tips (Satalec PS3, EMS PS, PS, PL1, PL2; Siroperio 1/2/3/7; Woodpecker P3; Acteon 10Z). Treatment is carried out under ≥3× magnification with emphasis on tissue preservation. The operator aims to achieve a stable blood clot emerging from the peri-implant pocket after instrumentation. No curettes or sharp instruments are used.
Also known as: MINST
Pocket closure at test site (implant site) - defined as PPD ≤5 mm, ≤1 bleeding point, no suppuration
* PPD ≤5 mm * ≤1 bleeding point * No suppuration Scale: 0-20 mm, the smaller the better, 4 mm is considered qualifying as a pocket closure and successful therapy
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months.
Change in Probing Pocket Depth (PPD)
Mean change in probing pocket depth (mm) at the study implant (test site), measured at six sites per implant using a UNC-15 periodontal probe. Scale: 0-20 mm, the bigger the better
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months
Change in Clinical Attachment Level (CAL)
Change in clinical attachment level (mm) at the study implant (test site), calculated as PPD + gingival recession at six sites per implant. Scale: 0-20 mm, the bigger the better
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months.
Radiographic Bone Level Changes
Change in peri-implant marginal bone levels assessed on standardized periapical radiographs using paralleling technique. Scale: 0-20 mm, the bigger the better
Time frame: Baseline and 12 months
Oral-Health-Related Quality of Life
Change in patient-reported oral-health-related quality of life measured using the OHIP-14 questionnaire. 14 questions with answers: yes/no/I don't know, none is considered better than others
Time frame: Baseline, 1 month, 3 months, 6 months, 9 months, 12 months
Treatment Time
Total duration (minutes) of the intervention visit (Visit 2), recorded from start to completion of instrumentation. Scale: 0-60 minutes, no outcome superior to other
Time frame: measured onyl once, during the intervention
Need for Additional or Rescue Therapy
Proportion of implants requiring additional treatment such as repeated non-surgical therapy, adjunctive antibiotics, surgical intervention, or explantation. Scale: yes/no
Time frame: Up to 12 months.
Full-Mouth pocket probing depth (PPD)
Changes in full-mouth PPD (scale 0-20 mm, bigger is better), 6 sites per tooth/implant
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months.
Number of participants with Post-operative Discomfort
Patient-reported need for analgesics and type of pain medication used after the intervention. Scale: yes/no, specify medication
Time frame: 1-month follow-up
Full-Mouth clinical attachment levels (CAL)
Changes in full-mouth CAL, 6 sites per tooth/implant (scale 0-20 mm, bigger is better)
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months.
Full-Mouth Plaque Score (FMPS)
Plaque levels at 6 sites per tooth/implant (1 for presence / 0 for absence, absence is better)
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months.
Full-Mouth Bleeding Score (FMBS)
Changes in full-mouth bleeding score: bleeding on probing at 6 sites per tooth/implant (1 for presence / 0 for absence, absence is better).
Time frame: Baseline, 3 months, 6 months, 9 months, 12 months.
Plan to share: Yes — The following pseudonymized datasets will be shared: Clinical measurements (PPD, CAL, BOP, plaque scores, keratinized tissue parameters) Radiographic bone level measurements PROMs (OHIP-14 responses) Microbiological plaque analysis results Treatment-related variables (treatment allocation, treatment time, need for rescue therapy) Demographic and baseline characteristics (age, sex, smoking status, BMI, education level) Identifiable personal data (name, date of birth, contact details, full medical record) will not be shared
Supporting information: Statistical analysis plan, Clinical study report
Time frame: After completion of primary analyses, expected April 2028
Access criteria: Pseudonymized data from the Brno study site will be shared with the coordinating research institution: King's College London, Faculty of Dentistry, Centre for Host-Microbiome Interactions. Data may also be shared with authorized members of the multicenter research team and regulatory bodies involved in oversight. Access will be restricted to authorized study personnel under data-sharing agreements compliant with GDPR and UK data protection regulations.
Started Jan 2026 (actual). Primary completion is estimated for Jan 2028, 24 months after the start.
Of 119 non-industry interventional studies with no phase under Peri-Implantitis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 46. This study's planned 24 months is close to that.
Counting every sponsor, half of 126 studies reached it within 26 months; a quarter within 12 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Anne's University Hospital Brno, Czech Republic